Nirali N. Shah

15.6k total citations · 7 hit papers
219 papers, 7.4k citations indexed

About

Nirali N. Shah is a scholar working on Oncology, Public Health, Environmental and Occupational Health and Hematology. According to data from OpenAlex, Nirali N. Shah has authored 219 papers receiving a total of 7.4k indexed citations (citations by other indexed papers that have themselves been cited), including 147 papers in Oncology, 58 papers in Public Health, Environmental and Occupational Health and 53 papers in Hematology. Recurrent topics in Nirali N. Shah's work include CAR-T cell therapy research (135 papers), Acute Lymphoblastic Leukemia research (52 papers) and Virus-based gene therapy research (28 papers). Nirali N. Shah is often cited by papers focused on CAR-T cell therapy research (135 papers), Acute Lymphoblastic Leukemia research (52 papers) and Virus-based gene therapy research (28 papers). Nirali N. Shah collaborates with scholars based in United States, Canada and United Kingdom. Nirali N. Shah's co-authors include Terry J. Fry, Constance M. Yuan, Maryalice Stetler‐Stevenson, Alan S. Wayne, Cindy Delbrook, Crystal L. Mackall, Rimas J. Orentas, Seth M. Steinberg, James N. Kochenderfer and Marianna Sabatino and has published in prestigious journals such as The Lancet, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Nirali N. Shah

199 papers receiving 7.3k citations

Hit Papers

T cells expressing CD19 chimeric antigen receptors for ac... 2012 2026 2016 2021 2014 2019 2012 2021 2022 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
    2014 2.2k citations Daniel W Lee, James N. Kochenderfer et al. profile →
  2. Mechanisms of resistance to CAR T cell therapy
    2019 690 citations Nirali N. Shah, Terry J. Fry profile →
  3. Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
    2012 440 citations Daniel W. Lee, Nirali N. Shah et al. Blood profile →
  4. Immunogenicity of CAR T cells in cancer therapy
    2021 208 citations Michael A. Pulsipher, Nirali N. Shah et al. profile →
  5. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
    2022 204 citations Sara Silbert, Nirali N. Shah et al. profile →
  6. Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL
    2021 200 citations Nirali N. Shah, Daniel W. Lee et al. profile →
  7. How I Treat Refractory CRS and ICANS Following CAR T-cell Therapy
    2023 94 citations Nirali N. Shah et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nirali N. Shah United States 34 6.0k 2.0k 1.8k 1.8k 1.6k 219 7.4k
Shannon L. Maude United States 33 7.7k 1.3× 2.5k 1.3× 2.1k 1.2× 2.2k 1.2× 1.9k 1.3× 107 9.2k
Zhaohui Zheng United States 17 5.6k 0.9× 2.1k 1.1× 1.8k 1.0× 1.7k 0.9× 1.5k 1.0× 32 6.5k
Vanessa Gonzalez United States 8 5.0k 0.8× 1.8k 0.9× 1.5k 0.8× 1.5k 0.8× 1.4k 0.9× 20 5.6k
Anne Chew United States 19 8.4k 1.4× 3.3k 1.6× 2.5k 1.4× 2.6k 1.4× 2.3k 1.5× 34 9.6k
Rimas J. Orentas United States 34 6.6k 1.1× 2.9k 1.5× 2.2k 1.2× 2.0k 1.1× 1.9k 1.2× 120 8.2k
Yolanda D. Mahnke United States 19 4.4k 0.7× 2.6k 1.3× 1.7k 0.9× 1.2k 0.7× 1.1k 0.7× 32 6.4k
Claudia Rössig Germany 35 4.4k 0.7× 2.4k 1.2× 1.4k 0.8× 1.4k 0.8× 951 0.6× 157 5.8k
Constance M. Yuan United States 31 4.2k 0.7× 1.7k 0.8× 1.5k 0.8× 1.2k 0.7× 996 0.6× 121 5.9k
Crystal L. Mackall United States 50 9.7k 1.6× 4.9k 2.4× 3.6k 2.0× 2.5k 1.4× 2.8k 1.8× 154 12.9k
Frederick L. Locke United States 34 5.2k 0.9× 1.4k 0.7× 1.4k 0.8× 1.2k 0.6× 1.2k 0.7× 307 6.0k

Countries citing papers authored by Nirali N. Shah

Since Specialization
Citations

This map shows the geographic impact of Nirali N. Shah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nirali N. Shah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nirali N. Shah more than expected).

Fields of papers citing papers by Nirali N. Shah

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nirali N. Shah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nirali N. Shah. The network helps show where Nirali N. Shah may publish in the future.

Co-authorship network of co-authors of Nirali N. Shah

This figure shows the co-authorship network connecting the top 25 collaborators of Nirali N. Shah. A scholar is included among the top collaborators of Nirali N. Shah based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nirali N. Shah. Nirali N. Shah is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lamble, Adam J., Sandra D. Bohling, Kara L. Davis, et al.. (2025). Harmonization on defining B‐cell recovery post CD19‐CAR T‐cell therapy in B‐cell acute lymphoblastic leukemia: An international consensus statement. HemaSphere. 9(11). e70247–e70247.
2.
Dreyzin, Alexandra, Lipei Shao, Yihua Cai, et al.. (2025). Immunophenotype of CAR T cells and apheresis products predicts response in CD22 CAR T cell trial for B cell acute lymphoblastic leukemia. Molecular Therapy. 33(7). 3360–3374. 3 indexed citations
3.
Underwood, Sarah, Jianjian Jin, Lipei Shao, et al.. (2024). T Cell Activators Exhibit Distinct Downstream Effects on Chimeric Antigen Receptor T Cell Phenotype and Function. ImmunoHorizons. 8(6). 404–414. 1 indexed citations
4.
5.
Harb, Roa, et al.. (2024). Diagnostic pitfalls in assessment of ferritin following CAR‐T‐cell therapy: Understanding the hook effect. Pediatric Blood & Cancer. 71(9). e31171–e31171.
6.
Rocco, Joseph M., Elizabeth Laidlaw, Bonnie Yates, et al.. (2024). Proliferation of a Novel CD3neg Hyperactivated T-Cell Population Characterizes Adult Hemophagocytic Lymphohistiocytosis and Associates with Disease Activity. Blood. 144(Supplement 1). 5382–5382. 1 indexed citations
7.
Duncan, Brynn B., et al.. (2024). Evolving strategies for addressing CAR T-cell toxicities. Cancer and Metastasis Reviews. 44(1). 17–17. 5 indexed citations
8.
Shah, Nirali N., et al.. (2024). CD19 CAR T cells for multiple sclerosis: Forging further into the new frontier. Med. 5(6). 482–484. 4 indexed citations
9.
DAVIS, J, Katharina E. Hayer, Sisi Zheng, et al.. (2024). PAX5 Loss Compromises CD22 Protein Levels and Responses to Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia. Blood. 144(Supplement 1). 4170–4170.
10.
Shahid, Zainab, Tania Jain, M. Veronica Dioverti, et al.. (2024). Best Practice Considerations by The American Society of Transplant and Cellular Therapy: Infection Prevention and Management After Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies. Transplantation and Cellular Therapy. 30(10). 955–969. 32 indexed citations
11.
Fuchs, Ephraim J., Leo Luznik, Javier Bolaños‐Meade, et al.. (2022). Hyperinflammatory syndrome resembling haemophagocytic lymphohistiocytosis following axicabtagene ciloleucel and brexucabtagene autoleucel. British Journal of Haematology. 199(5). 720–727. 13 indexed citations
12.
Molina, John C., Ting Zhou, Constance M. Yuan, et al.. (2022). Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation. Journal for ImmunoTherapy of Cancer. 10(5). e004483–e004483. 31 indexed citations
13.
Dreyzin, Alexandra, Sandhya R. Panch, Haneen Shalabi, et al.. (2022). Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells. Molecular Therapy — Methods & Clinical Development. 28. 51–61. 9 indexed citations
14.
Molina, John C. & Nirali N. Shah. (2021). CAR T cells better than BiTEs. Blood Advances. 5(2). 602–606. 20 indexed citations
15.
Mikkilineni, Lekha, Bonnie Yates, Seth M. Steinberg, et al.. (2021). Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days. Blood Advances. 5(23). 5312–5322. 47 indexed citations
16.
Molina, John C., Seth M. Steinberg, Bonnie Yates, et al.. (2021). Factors Impacting Overall and Event-Free Survival following Post-Chimeric Antigen Receptor T Cell Consolidative Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy. 28(1). 31.e1–31.e9. 12 indexed citations
17.
Yates, Bonnie, Alexander Ling, Constance M. Yuan, et al.. (2021). Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy. Blood Advances. 6(7). 2167–2182. 35 indexed citations
18.
Masih, Katherine E., John A. Ligon, Bonnie Yates, et al.. (2021). Consequences of hemophagocytic lymphohistiocytosis‐like cytokine release syndrome toxicities and concurrent bacteremia. Pediatric Blood & Cancer. 68(10). e29247–e29247. 10 indexed citations
19.
Wong, Winghing, Sima Bhatt, Kathryn Trinkaus, et al.. (2020). Engraftment of rare, pathogenic donor hematopoietic mutations in unrelated hematopoietic stem cell transplantation. Science Translational Medicine. 12(526). 36 indexed citations
20.
Ramakrishna, Sneha, Steven L. Highfill, Sang M. Nguyen, et al.. (2019). Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence. Clinical Cancer Research. 25(17). 5329–5341. 115 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shannon L. Maude Breakdown of academic impact, for papers by Zhaohui Zheng Breakdown of academic impact, for papers by Vanessa Gonzalez Breakdown of academic impact, for papers by Anne Chew Breakdown of academic impact, for papers by Rimas J. Orentas Breakdown of academic impact, for papers by Yolanda D. Mahnke Breakdown of academic impact, for papers by Claudia Rössig Breakdown of academic impact, for papers by Constance M. Yuan Breakdown of academic impact, for papers by Crystal L. Mackall Breakdown of academic impact, for papers by Frederick L. Locke
Rankless by CCL
2026